Category: MassDevice Q&A
Accuray CEO Euan Thomson discusses the finer points of robotic prostate cancer treatment and the motivation behind a head-to-head clinical trial pitting its CyberKnife radiosurgery system against Intuitive Surgical's da Vinci.
In an exclusive podcast interview with MassDevice.com, Rosa told us about the company's beginnings, his optimism for the still-sluggish heart failure treatment landscape and why it's so important that patients can disconnect from Sunshine Heart's flagship, outside-the-bloodstream C-Pulse heart assist device.
Click here to listen to the podcast
"In the U.S., for Class III heart failure there are about 1.5 million patients," Sunshine Heart CEO David Rosa told MassDevice.com in an exclusive podcast interview. "That's about 7 times the Class IV market, which is traditionally where LVADs participate."
The second part of a MassDevice.com conversation with Steve Rusckowski, the CEO of Philips Healthcare.
(Back to page 1)
MassDevice.com: I'm interested in your thoughts on the increased pressure to take costs out of the system as well as to improve outcomes. Is that a damper on innovation?
In his last interview as CEO of Philips Healthcare before taking the corner office at Quest Diagnostics, Steve Rusckowski tells MassDevice why 2011 was a tough year for the world's 7th-largest medical device maker, why things are looking up this year and how innovation can go hand-in-hand with lower costs.
It's not exactly news that the med-tech industry is under pressure from a variety of fronts – an uncertain regulatory environment, a looming tax burden and, not least, downward pricing pressure from its health care provider customers.
MassDevice discusses innovation, robotic surgery and Silicon Valley culture with Intuitive Surgical CEO Gary Guthart.
Gary Guthart knows a little something about disruptive innovation.
The threat that the fusion of humans and medical machines may leave patients vulnerable to the hackers and bugs of the digital world is beginning to resonate with device makers.
Karen Sandler was 31 years old, working at a non-profit organization providing free legal help to computer programmers, when she was diagnosed with an enlarged heart and informed that she'd need a machine to help keep her alive.
Her mother accompanied her the day a doctor recommended that Sandler undergo surgery to implant a medical device into her chest. He handed Sandler a pager-sized machine called a cardioverter defibrillator – a miniature, implantable equivalent of having EMTs follow her around all day with defibrillator paddles should her heart stop.
Accuray CEO Euan Thomson tells MassDevice about being a small fish in a big pond, managing growing pains and his strategies for breaking out in a well-established market.
When Euan Thomson landed in the corner office at radiosurgery device maker Accuray (NSDQ:ARAY) in 2002, the company was just preparing to penetrate a very well-established market.
